Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Non-Current Deferred Tax Liability came in at $6.6 billion in Q2 2026, up 73.94% year-over-year from $3.8 billion in Q2 2025, and down 5.75% quarter-over-quarter from $7.0 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $6.6 billion for Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability rose 73.94% year-over-year to $6.6 billion; the TTM figure through Jun 2026 stood at $6.6 billion (up 73.94% YoY), while the FY2025 annual figure was $6.8 billion, up 177.41% from the prior year.
- Non-Current Deferred Tax Liability came in at $6.6 billion for Q2 2026 at Johnson & Johnson, down from $7.0 billion in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.5 billion in Q1 2022 to a low of $2.4 billion in Q1 2025.
- Average Non-Current Deferred Tax Liability over 5 years is $4.5 billion, with a median of $4.0 billion recorded in 2023.
- Year-over-year, Non-Current Deferred Tax Liability tumbled 46.97% in 2023 and jumped 188.76% in 2026.
- Over 5 years, Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then tumbled by 35.44% to $3.2 billion in 2023, then retreated by 23.33% to $2.4 billion in 2024, then surged by 177.41% to $6.8 billion in 2025, then slipped by 2.69% to $6.6 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $6.6 billion in Q2 2026, $7.0 billion in Q1 2026, and $6.8 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 6.61 Bn |
| Mar 29, 2026 | 7.01 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Oct 1, 2023 | 2.62 Bn |
| Jul 2, 2023 | 3.63 Bn |
| Apr 2, 2023 | 4.42 Bn |
| Jan 1, 2023 | 3.99 Bn |
| Oct 2, 2022 | 4.95 Bn |
| Jul 3, 2022 | 5.02 Bn |
| Apr 3, 2022 | 6.42 Bn |
| Jan 2, 2022 | 7.49 Bn |
| Oct 3, 2021 | 7.15 Bn |